Ketamine in treatment-resistant major depressio

niversity of Kuopio (Finland)0 个研究点目标入组 100 人开始时间: 2006年7月3日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•1. Major depression disorder (Diagnostic and Statistical Manual of mental disorders [DSM-IV] 296.2 or 296.3) or type two bipolar affective disorder, last phase with depressive symptoms
•2. Depressive symptoms at least at moderate level (Hamilton Depression rating scale [HAMD-17] score 16 or more)
•3. Age 18 to 55 years
•4. Insufficient response to at least two different antidepressants
•5. No substantial changes in current antidepressant treatment during the last four weeks and changes in pharmacotherapy have not been planned for the following two weeks

•1. Serious somatic disease (cardiac insufficiency, untreated hypertension, increased cerebral pressure, diseases in the central nervous system, increased intraocular pressure (glaucoma), hepatic disease, porphyria, thyroid disease, infection in lungs or in upper respiratory track, epilepsy)
•2. Theophyllin medication, or use of anticonvulsants or drugs affecting glutamatergic system
•3. Proneness to psychotic symptoms (psychosis diagnosed in first degree relatives)
•4. Increased suicide risk
•5. Pregnancy
•6. Substance abuse during the last three weeks
•7. Exceptionally large dosage of antidepressants (dosage per day more than recommended in Pharmaca Fennica) (this was amended 19/12/2006)
•8. Exceptionally large dosage of benzodiazepines (diazepam equivalent dose more than 30 mg/day)

发起方

niversity of Kuopio (Finland)